BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Lymphoma AND TFEB, TCFEB, 7942, ENSG00000112561, P19484, AlphaTFEB AND Treatment
6 results:

  • 1. Resistance to abemaciclib is associated with increased metastatic potential and lysosomal protein deregulation in breast cancer cells.
    Scheidemann ER; Demas DM; Hou C; Ma J; He W; Sharma G; Schultz E; Weilbaecher KN; Shajahan-Haq AN
    Mol Carcinog; 2024 Feb; 63(2):209-223. PubMed ID: 37818798
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Aberrant SPOP-CHAF1A ubiquitination axis triggers tumor autophagy that endows a therapeutical vulnerability in diffuse large B cell lymphoma.
    Yan W; Shi X; Wang H; Liao A; Yang W
    J Transl Med; 2022 Jun; 20(1):296. PubMed ID: 35773729
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Disrupting the MYC-tfeb Circuit Impairs Amino Acid Homeostasis and Provokes Metabolic Anergy.
    Fernandez MR; Schaub FX; Yang C; Li W; Yun S; Schaub SK; Dorsey FC; Liu M; Steeves MA; Ballabio A; Tzankov A; Chen Z; Koomen JM; Berglund AE; Cleveland JL
    Cancer Res; 2022 Apr; 82(7):1234-1250. PubMed ID: 35149590
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Cyclodextrin Prevents Abdominal Aortic Aneurysm via Activation of Vascular Smooth Muscle Cell Transcription Factor EB.
    Lu H; Sun J; Liang W; Chang Z; Rom O; Zhao Y; Zhao G; Xiong W; Wang H; Zhu T; Guo Y; Chang L; Garcia-Barrio MT; Zhang J; Chen YE; Fan Y
    Circulation; 2020 Aug; 142(5):483-498. PubMed ID: 32354235
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Identification of ANXA2 (annexin A2) as a specific bleomycin target to induce pulmonary fibrosis by impeding tfeb-mediated autophagic flux.
    Wang K; Zhang T; Lei Y; Li X; Jiang J; Lan J; Liu Y; Chen H; Gao W; Xie N; Chen Q; Zhu X; Liu X; Xie K; Peng Y; Nice EC; Wu M; Huang C; Wei Y
    Autophagy; 2018; 14(2):269-282. PubMed ID: 29172997
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Identification of apilimod as a first-in-class PIKfyve kinase inhibitor for treatment of B-cell non-Hodgkin lymphoma.
    Gayle S; Landrette S; Beeharry N; Conrad C; Hernandez M; Beckett P; Ferguson SM; Mandelkern T; Zheng M; Xu T; Rothberg J; Lichenstein H
    Blood; 2017 Mar; 129(13):1768-1778. PubMed ID: 28104689
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.